| Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) M Herdman, C Gudex, A Lloyd, MF Janssen, P Kind, D Parkin, G Bonsel, ... Quality of life research 20, 1727-1736, 2011 | 7717 | 2011 |
| Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets B Van Hout, MF Janssen, YS Feng, T Kohlmann, J Busschbach, D Golicki, ... Value in health 15 (5), 708-715, 2012 | 1862 | 2012 |
| Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study MF Janssen, AS Pickard, D Golicki, C Gudex, M Niewada, L Scalone, ... Quality of life research 22, 1717-1727, 2013 | 1516 | 2013 |
| Self-reported population health: an international perspective based on EQ-5D A Szende, B Janssen, J Cabases Springer Nature, 2014 | 789 | 2014 |
| Psychometric properties of the EQ-5D-5L: a systematic review of the literature YS Feng, T Kohlmann, MF Janssen, I Buchholz Quality of Life Research 30, 647-673, 2021 | 349 | 2021 |
| Comparing the standard EQ-5D three-level system with a five-level version MF Janssen, E Birnie, JA Haagsma, GJ Bonsel Value in Health 11 (2), 275-284, 2008 | 308 | 2008 |
| Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries MF Janssen, GJ Bonsel, N Luo Pharmacoeconomics 36, 675-697, 2018 | 270 | 2018 |
| A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D I Buchholz, MF Janssen, T Kohlmann, YS Feng Pharmacoeconomics 36, 645-661, 2018 | 261 | 2018 |
| Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries MF Janssen, A Szende, J Cabases, JM Ramos-Goñi, G Vilagut, HH König The European Journal of Health Economics 20, 205-216, 2019 | 236 | 2019 |
| Validity of EQ-5D-5L in stroke D Golicki, M Niewada, J Buczek, A Karlińska, A Kobayashi, MF Janssen, ... Quality of life research 24, 845-850, 2015 | 235 | 2015 |
| Methods for analysing and reporting EQ-5D data N Devlin, D Parkin, B Janssen Springer Nature, 2020 | 200 | 2020 |
| The use of the EQ‐5D preference‐based health status measure in adults with type 2 diabetes mellitus MF Janssen, EI Lubetkin, JP Sekhobo, AS Pickard Diabetic medicine 28 (4), 395-413, 2011 | 194 | 2011 |
| Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients D Golicki, M Niewada, A Karlińska, J Buczek, A Kobayashi, MF Janssen, ... Quality of Life Research 24, 1555-1563, 2015 | 148 | 2015 |
| Introducing the composite time trade-off: a test of feasibility and face validity BMF Janssen, M Oppe, MM Versteegh, EA Stolk The European Journal of Health Economics 14, 5-13, 2013 | 137 | 2013 |
| US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples R Jiang, MFB Janssen, AS Pickard Quality of Life Research 30, 803-816, 2021 | 106 | 2021 |
| Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets B Mulhern, Y Feng, K Shah, MF Janssen, M Herdman, B van Hout, ... Pharmacoeconomics 36, 699-713, 2018 | 103 | 2018 |
| Quantification of the level descriptors for the standard EQ-5D three-level system and a five-level version according to two methods MF Janssen, E Birnie, GJ Bonsel Quality of Life Research 17, 463-473, 2008 | 91 | 2008 |
| Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK P Swinburn, A Lloyd, KS Boye, E Edson-Heredia, L Bowman, B Janssen Value in Health 16 (8), 1156-1162, 2013 | 83 | 2013 |
| Evaluating equivalency between response systems: application of the Rasch model to a 3-level and 5-level EQ-5D AS Pickard, T Kohlmann, MF Janssen, G Bonsel, S Rosenbloom, D Cella Medical care 45 (9), 812-819, 2007 | 75 | 2007 |
| Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices MF Janssen, E Birnie, GJ Bonsel Quality of life research 16, 895-904, 2007 | 72 | 2007 |
